Learn More About The 2026 Summit
This July, join in vivo experts to discuss practical questions about targeting, off‑tissue activity, manufacturability, and regulatory readiness. The 5th In Vivo Cell Engineering & Gene Editing Summit is your opportunity to benchmark strategies, build partnerships, and take actionable insights back to your programs.
Learn more about why you should connect with trailblazers from firms like Alaya Bio, AllerGene AI, Kite Pharma, Azelea Therapeutics, Stylus Medicine, Innorna, and many more.
Why In Vivo Might be the Biggest Paradigm Shift for Cell and Gene Therapies
In vivo cell engineering and in vivo gene editing have rapidly transformed from early scientific concepts into the most-watched frontier in cell and gene therapy.
Why Ex Vivo Companies Can’t Afford to Ignore the Future of In Vivo Therapies
For over a decade, ex vivo platforms have shaped the foundational breakthroughs in cell and gene therapy.
How Asia’s IIT Ecosystem Is Accelerating In Vivo Clinical Development in 2026
For in vivo pipeline companies, Asia’s rapidly evolving IIT environment is redefining how early clinical data, manufacturing partnerships, and global strategy come together.
Benchmarking Your In Vivo Pipeline for 2026: Clinical Signals, Asia IIT Acceleration and What Top Biotechs Are Prioritizing Now
Companies with active in vivo pipelines face a different set of pressures than those still exploring the space.
From Early Bet to Market Leader: The In Vivo CAR-T Opportunity
If you have been tracking the advanced therapies landscape recently, it has been hard to miss the growing momentum behind in vivo CAR‑T.